$2.7 Billion Worldwide Pet Diabetes Care Industry to 2027 - Players Include ACON Laboratories, Allison Medical, i-SENS and Trividia Health
December 15, 2022 04:50 ET
|
Research and Markets
Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Pet Diabetes Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
September 15, 2021 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in...
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
February 03, 2021 07:10 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...